株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

開放隅角緑内障(OAG)- 疫学予測 2028年

Open-Angle Glaucoma - Epidemiology Forecast to 2030

発行 DelveInsight Business Research LLP 商品コード 534932
出版日 ページ情報 英文 100 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.51円で換算しております。
開放隅角緑内障(OAG)- 疫学予測 2028年 Open-Angle Glaucoma - Epidemiology Forecast to 2030
出版日: 2020年04月01日 ページ情報: 英文 100 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)における開放隅角緑内障(OAG)の2017年の有病数は981万9,080人と推計されています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)における開放隅角緑内障(OAG)市場を調査し、疾病の概要や、国別の疫学、病型・臨床症状別の有病数の推移と予測を詳細にまとめています。

目次

第1章 主要洞察

第2章 開放隅角緑内障(OAG)市場の概要

  • 開放隅角緑内障(OAG)の市場シェア(実績値)
  • 開放隅角緑内障(OAG)の市場シェア(予測値)

第3章 疾病背景と概要:開放隅角緑内障(OAG)

  • イントロダクション
  • 分類
  • 兆候と症状
  • リスク要因
  • 臨床症状
  • 遺伝的基盤
    • ミオシリン(MYOC, OMIM #601652)
    • オプチニューリン(OPTN, OMIM #602432)
    • TANK結合キナーゼ-1(TANK-binding Kinase-1)
    • WDリピート36(WDR36, OMIM 609669)
  • 診断

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国の開放隅角緑内障(OAG)の総有病数
  • 主要7カ国の開放隅角緑内障(OAG)の診断数

第5章 米国の開放隅角緑内障(OAG)の疫学

  • 開放隅角緑内障(OAG)の総有病数
  • 開放隅角緑内障(OAG)の診断数
  • 開放隅角緑内障(OAG)の有病数:性別
  • 開放隅角緑内障(OAG)の有病数:年齢別
  • 開放隅角緑内障(OAG)の有病数:病型別

第6章 EU5カ国の開放隅角緑内障(OAG)の疫学

  • ドイツ
    • 開放隅角緑内障(OAG)の総有病数
    • 開放隅角緑内障(OAG)の診断数
    • 開放隅角緑内障(OAG)の有病数:性別
    • 開放隅角緑内障(OAG)の有病数:年齢別
    • 開放隅角緑内障(OAG)の有病数:病型別
  • フランス
    • 開放隅角緑内障(OAG)の総有病数
    • 開放隅角緑内障(OAG)の診断数
    • 開放隅角緑内障(OAG)の有病数:性別
    • 開放隅角緑内障(OAG)の有病数:年齢別
    • 開放隅角緑内障(OAG)の有病数:病型別
  • イタリア
    • 開放隅角緑内障(OAG)の総有病数
    • 開放隅角緑内障(OAG)の診断数
    • 開放隅角緑内障(OAG)の有病数:性別
    • 開放隅角緑内障(OAG)の有病数:年齢別
    • 開放隅角緑内障(OAG)の有病数:病型別
  • スペイン
    • 開放隅角緑内障(OAG)の総有病数
    • 開放隅角緑内障(OAG)の診断数
    • 開放隅角緑内障(OAG)の有病数:性別
    • 開放隅角緑内障(OAG)の有病数:年齢別
    • 開放隅角緑内障(OAG)の有病数:病型別
  • 英国
    • 開放隅角緑内障(OAG)の総有病数
    • 開放隅角緑内障(OAG)の診断数
    • 開放隅角緑内障(OAG)の有病数:性別
    • 開放隅角緑内障(OAG)の有病数:年齢別
    • 開放隅角緑内障(OAG)の有病数:病型別

第7章 日本の開放隅角緑内障(OAG)の疫学

  • 開放隅角緑内障(OAG)の総有病数
  • 開放隅角緑内障(OAG)の診断数
  • 開放隅角緑内障(OAG)の有病数:性別
  • 開放隅角緑内障(OAG)の有病数:年齢別
  • 開放隅角緑内障(OAG)の有病数:病型別

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

図表

List of Tables

  • Table 1 Summary of OAG Epidemiology and Key Events (2017-2030)
  • Table 2 Clinical Stages of Primary Open-Angle Glaucoma
  • Table 3 Two Classes of Primary Open-Angle Glaucoma (POAG) Mutations
  • Table 4 Genes associated with the risk of POAG
  • Table 5 Innate and adaptive immunity changes in POAG
  • Table 6 The definitions and levels of evidence to rate individual studies
  • Table 7 Recommendations for care are formed based on the body of the evidence. The body of evidence quality ratings are defined by GRADE
  • Table 8 Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines
  • Table 9 Total Prevalence of Glaucoma in the 7MM (2017-2030)
  • Table 10 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM (2017-2030)
  • Table 11 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM (2017-2030)
  • Table 12 Total Prevalence of Glaucoma in the United States (2017-2030)
  • Table 13 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the US (2017-2030)
  • Table 14 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the US (2017-2030)
  • Table 15 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States(2017-2030)
  • Table 16 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States (2017-2030)
  • Table 17 Total Prevalence of Glaucoma in Germany (2017-2030)
  • Table 18 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Germany (2017-2030)
  • Table 19 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2030)
  • Table 20 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2030)
  • Table 21 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2030)
  • Table 22 Total Prevalence of Glaucoma in France (2017-2030)
  • Table 23 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in France (2017-2030)
  • Table 24 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2030)
  • Table 25 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2030)
  • Table 26 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2030)
  • Table 27 Total Prevalence of Glaucoma in Italy (2017-2030)
  • Table 28 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Italy (2017-2030)
  • Table 29 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2030)
  • Table 30 Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2030)
  • Table 31 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2030)
  • Table 32 Total Prevalence of Glaucoma in Spain (2017-2030)
  • Table 33 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Spain (2017-2030)
  • Table 34 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2030)
  • Table 35 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2030)
  • Table 36 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2030)
  • Table 37 Total Prevalence of Glaucoma in the United Kingdom (2017-2030)
  • Table 38 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United Kingdom (2017-2030)
  • Table 39 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom (2017-2030)
  • Table 40 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom (2017-2030)
  • Table 41 Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom (2017-2030)
  • Table 42 Total Prevalence of Glaucoma in Japan (2017-2030)
  • Table 43 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Japan (2017-2030)
  • Table 44 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2030)
  • Table 45 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2030)
  • Table 46 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2030)

List of Figures

  • Figure 1 Aqueous humor production and flow
  • Figure 2 Development of Glaucoma
  • Figure 3 Classification of Open-Angle Glaucoma
  • Figure 4 Symptoms of Open-Angle Glaucoma
  • Figure 5 Risk Factors Associated with POAG
  • Figure 6 Factors Contributing to the Pathophysiology of Glaucomatous Neurodegeneration
  • Figure 7 Pathophysiology of Primary Open-Angle Glaucoma
  • Figure 8 Proposed pathways for normal secretion of myocilin into the aqueous humor and for secretion reduced by a MYOC mutation
  • Figure 9 Diagnosis of Primary Open-Angle Glaucoma (POAG)
  • Figure 10 Glaucoma Assessment (Optic Nerve)
  • Figure 11 Total Prevalence of Glaucoma in the 7MM (2017-2030)
  • Figure 12 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM (2017-2030)
  • Figure 13 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM (2017-2030)
  • Figure 14 Total Prevalence of Glaucoma in the United States (2017-2030)
  • Figure 15 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the US (2017-2030)
  • Figure 16 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the US (2017-2030)
  • Figure 17 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States (2017-2030)
  • Figure 18 Type-Specific Diagnosed Prevalence of OAG in the United States (2017-2030)
  • Figure 19 Total Prevalence of Glaucoma in Germany (2017-2030)
  • Figure 20 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Germany (2017-2030)
  • Figure 21 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2030)
  • Figure 22 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2030)
  • Figure 23 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2017-2030)
  • Figure 24 Total Prevalence of Glaucoma in France (2017-2030)
  • Figure 25 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in France (2017-2030)
  • Figure 26 Gender-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2030)
  • Figure 27 Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2030)
  • Figure 28 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2017-2030)
  • Figure 29 Total Prevalence of Glaucoma in Italy (2017-2030)
  • Figure 30 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Italy (2017-2030)
  • Figure 31 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2030)
  • Figure 32 Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2030)
  • Figure 33 Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2017-2030)
  • Figure 34 Total Prevalence of Glaucoma in Spain (2017-2030)
  • Figure 35 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Spain (2017-2030)
  • Figure 36 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2030)
  • Figure 37 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2030)
  • Figure 38 Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2017-2030)
  • Figure 39 Total Prevalence of Glaucoma in the United Kingdom (2017-2030)
  • Figure 40 Total Diagnosed Prevalent Population of OAG in the United Kingdom (2017-2030)
  • Figure 41 Gender-Specific Diagnosed Prevalence of OAG in the United Kingdom (2017-2030)
  • Figure 42 Age-Specific Diagnosed Prevalence of OAG in the United Kingdom (2017-2030)
  • Figure 43 Type-Specific Diagnosed Prevalence of OAG in the United Kingdom (2017-2030)
  • Figure 44 Total Prevalence of Glaucoma in Japan (2017-2030)
  • Figure 45 Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Japan (2017-2030)
  • Figure 46 Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2030)
  • Figure 47 Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2030)
  • Figure 48 Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2017-2030)
目次
Product Code: DIEI0156

DelveInsight's Open-angle glaucoma (OAG)-Epidemiology Forecast-2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of OAG in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Open-angle glaucoma (OAG) - Disease Understanding

Open-angle glaucoma (OAG) is a progressive form of glaucoma in which the channel formed between the iris and the cornea remains open and tissue changes along the channel, which gradually reduces the drainage of the aqueous humor through the trabecular meshwork of the eye's anterior chamber. It is the most common form of glaucoma which accounts for the majority of the glaucoma cases. The term "Open-Angle" refers to the angle where the iris meets the cornea and is as wide and open as it should be. OAG is mainly caused by the slow clogging of the drainage canals, resulting in increased eye pressure.

The OAG is primarily divided into two subtypes, i.e., Primary OAG and Secondary OAG. The risk factors of open-angle glaucoma are divided into four categories, general factors, ocular factors, nonocular factors, and ocular hypertension.

Open-angle glaucoma (OAG) - Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Glaucoma in the 7MM, Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM, Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM, Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM and Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM scenario of OAG in the 7MM countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

As per DelveInsight's analysis, a higher percentage of diagnosed prevalence of OAG was observed for females, in comparison to males, in all the 7MM countries. DelveInsight's analysts have assessed that the total prevalent population of Glaucoma in the 7MM was 9,819,080 in 2017. In addition to this it was also assessed that among those with glaucoma in the 7MM, more than 8.5 million were diagnosed with OAG. DelveInsight's estimate suggests that the United States witnessed the highest number of cases with OAG, as compared to other 7MM countries. As per DelveInsight's estimates, the country accounted for approximately 2,749,378 cases in 2017.

Among the EU-5 countries, Germany accounted for the highest number of glaucoma cases in 2017, which was observed to be equivalent to more than 25% of the total affected population in this region. The number of cases for glaucoma was observed to be 1,041,889 in the country for 2017. However, Spain accounted for the lowest number of glaucoma cases in 2017, which was approximately 13.33% of the total affected population of EU-5 countries. According to DelveInsight's analysts, Japan accounted for the second-highest number of OAG patients, i.e., 28.79% of the total OAG population in the 7MM countries.

According to DelveInsight's assessment, it has been observed that OAG prevalence varied across the 7MM countries, based on the age-specific prevalence of the disease. For instance, the highest proportion was observed in the 70-79 years age group in the US, while in the EU-5 countries, people aged ≥80 years accounted for the maximum patient pool. In contrast, the middle age population aged 50-59 years contributed to the highest patient pool in Japan.

Report Scope:

  • The report covers a detailed overview of Open-angle glaucoma explaining its causes, symptoms, classification, pathophysiology, and diagnosis.
  • The report provides insight into the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Open-angle glaucoma
  • The report helps to recognize the growth opportunities in the 7MM countries with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by total Prevalence of Glaucoma in the 7MM, Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM, Gender-Specific Diagnosed Prevalence in the 7MM, Age-Specific Diagnosed Prevalence in the 7MM, and Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM.

Open-angle glaucoma Report Key Strengths

  • 11 Year Forecast
  • 7MM Coverage
  • Total Prevalence of Glaucoma
  • Total Diagnosed Prevalent Population of Open-Angle Glaucoma
  • Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma
  • Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma
  • Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma

Open-angle glaucoma Report Assessment

  • Patient segmentation
  • Disease risk and burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Open-Angle Glaucoma

3. Open-Angle Glaucoma (OAG): Epidemiology Overview at a Glance

  • 3.1. Total Prevalent Cases of OAG in 2017
  • 3.2. Total Prevalent Cases of OAG in 2030

4. Open-Angle Glaucoma: Disease Background and Overview

  • 4.1. Introduction
  • 4.2. Classification of Open-Angle Glaucoma
  • 4.3. Signs and Symptoms of Open-Angle Glaucoma
  • 4.4. Risk Factors of Primary Open-Angle Glaucoma (POAG)
    • 4.4.1. General
    • 4.4.2. Ocular
    • 4.4.3. Nonocular
    • 4.4.4. Ocular Hypertension
  • 4.5. Pathophysiology of Primary Open-Angle Glaucoma (POAG)
  • 4.6. Genes Involved in Primary Open-Angle Glaucoma
    • 4.6.1. Myocilin
    • 4.6.2. Optineurin
    • 4.6.3. TANK-binding Kinase-1 (TBK1)
    • 4.6.4. WD-repeat domain 36 (WDR36, OMIM 609669)
  • 4.7. Biomarkers associated with Primary Open Angle Glaucoma (POAG)
  • 4.8. Diagnosis of Open-Angle Glaucoma
    • 4.8.1. Diagnosis of Primary Open-Angle Glaucoma
    • 4.8.2. Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines

5. Case Reports

  • 5.1. Managing Juvenile Open-Angle Glaucoma
  • 5.2. Visual improvement following glaucoma surgery: a case report
  • 5.3. Evidence-based medicine in glaucoma surgery

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. Epidemiology Methodology
  • 6.3. Total Prevalence of Glaucoma in the 7MM
  • 6.4. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the 7MM
  • 6.5. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the 7MM

7. United States Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Total Prevalence of Glaucoma in the United States
  • 7.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United States
  • 7.4. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States
  • 7.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States
  • 7.6. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States

8. EU5 Epidemiology

  • 8.1. Germany Epidemiology
    • 8.1.1. Assumptions and Rationale
    • 8.1.2. Total Prevalence of Glaucoma in Germany
    • 8.1.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Germany
    • 8.1.4. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
    • 8.1.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
    • 8.1.6. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany
  • 8.2. France Epidemiology
    • 8.2.1. Assumptions and rationale
    • 8.2.2. Total Prevalence of Glaucoma in France
    • 8.2.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in France
    • 8.2.4. Gender-specific Diagnosed Prevalence of Open-Angle Glaucoma in France
    • 8.2.5. Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in France
    • 8.2.6. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France
  • 8.3. Italy Epidemiology
    • 8.3.1. Assumptions and Rationale
    • 8.3.2. Total Prevalence of Glaucoma in Italy
    • 8.3.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Italy
    • 8.3.4. Gender-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
    • 8.3.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
    • 8.3.6. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy
  • 8.4. Spain Epidemiology
    • 8.4.1. Assumptions and Rationale
    • 8.4.2. Total Prevalence of Glaucoma in Spain
    • 8.4.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Spain
    • 8.4.4. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
    • 8.4.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
    • 8.4.6. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain
  • 8.5. United Kingdom Epidemiology
    • 8.5.1. Assumptions and Rationale
    • 8.5.2. Total Prevalence of Glaucoma in the United Kingdom
    • 8.5.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in the United Kingdom
    • 8.5.4. Gender- Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom
    • 8.5.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom
    • 8.5.6. Type - Specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom

9. Japan Epidemiology

  • 9.1. Assumptions and Rationale
  • 9.2. Total Prevalence of Glaucoma in Japan
  • 9.3. Total Diagnosed Prevalent Population of Open-Angle Glaucoma in Japan
  • 9.4. Gender-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan
  • 9.5. Age-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan
  • 9.6. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan

10. Appendix

  • 10.1. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight